Gregory Laird
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$7.2MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $7.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 23, 2021 | NIH | SBIR Phase I HIV-1 EnvLRS: a scalable, sequence-based assay for in-depth assessment of HIV-1 bNAb resistance | $300K | Accelevir Diagnostics, LLC |
| Jul 7, 2021 | NIH | SBIR Phase I IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials | $600K | Accelevir Diagnostics, LLC |
| Dec 12, 2019 | NIH | SBIR Phase I Development of Intact Proviral DNA Assays for SIV and SHIV | $300K | Accelevir Diagnostics, LLC |
| Aug 15, 2018 | NIH | SBIR Phase I Development of a quantitative assay for intact HIV DNA measures in tissue | $300K | Accelevir Diagnostics, LLC |
| 2018 | NIH | SBIR Phase II A Novel Test to Measure Latent Virus in HIV-1 Infected Patients | $2.0M | Accelevir Diagnostics, LLC |
| Sep 18, 2017 | NSF | SBIR Phase II SBIR Phase II: Development and Optimization of a New Molecular Test to quantify Latent HIV-1 in Samples from HIV-1 Infected Individuals. | $1.2M | Accelevir Diagnostics, LLC |
| Sep 15, 2017 | NSF | SBIR Phase II SBIR Phase II: Development and Optimization of a New Molecular Test to quantify Latent HIV-1 in Samples from HIV-1 Infected Individuals. | $1.2M | Accelevir Diagnostics, LLC |
| Aug 18, 2017 | NIH | SBIR Phase I Highly specific HIV mRNA detection method with global subtype coverage to monitor latency reversal in patients | $289K | Accelevir Diagnostics, LLC |
| Aug 1, 2017 | NIH | SBIR Phase I Development of a next generation quantitative viral outgrowth assay QVOA for the standardized measurement of the HIV latent reservoir | $297K | Accelevir Diagnostics, LLC |
| Jul 1, 2016 | NSF | SBIR Phase I SBIR Phase I: Development and optimization of a new molecular test to quantify latent HIV-1 in samples from HIV-1 infected individuals. | $225K | Accelevir Diagnostics, LLC |
| Jun 27, 2016 | NIH | SBIR Phase I A Novel Test to Measure Latent Virus in HIV-1 Infected Patients | $259K | Accelevir Diagnostics, LLC |
| Jun 24, 2016 | NSF | SBIR Phase I SBIR Phase I: Development and optimization of a new molecular test to quantify latent HIV-1 in samples from HIV-1 infected individuals. | $225K | Accelevir Diagnostics, LLC |
Peer ranks
Federal funding#139
Awards as PI#97
Patents#505
Companies
- Accelevir Diagnostics, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.